Frontlight ResearchEarly access
Active, not recruitingNo phase
A Study to Compare Digital Disease Monitoring of Patients With csU (Telemedicine to Face-to-Face Visits) in Germany
Key facts
- Who runs it
- Novartis Pharmaceuticals
- Where
- Germany19 sites in 1 countryChoose a country to see its sites
- Trial code
- Status
- Active, not recruiting
- People taking part
- 116 people enrolled
- Started
- 11 Jun 2024
- Ended
- 31 Dec 2025
- Type of study
- Observational, 2 groups
- Treatments tested
- Collection of patient data
- Record updated
- 16 July 2025
Who can take part
- Age
- 18 years to 80 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 7 criteriaShow less
Who can take part
- Adults aged 18 and above
- Written informed consent for participation obtained from the subject
- Diagnosed chronic spontaneous urticaria
- Medical therapy for CSU
- Concomitant chronic inducible urticaria is allowed
- Willing and be able to perform digital visits
Who cannot take part
- Simultaneous participation in any clinical trial
This trial has no sites in United States.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
This is a multicenter, non-randomized, non-interventional two-cohort study with prospective collection of primary data on monitoring of Chronic spontaneous urticaria (CSU) patients by telemedicine or F2F visits in routine clinical care. This implementation science study will collect data from patients during routine CSU monitoring via F2F visits or teledermatological visits. The study will be representative for the real-world patient CSU population in Germany.
The 2 groups in the trial
- arm A: F2F
Monitoring via face to face (F2F) visits
Treatment: Collection of patient data
- Arm B: Teledermatology
Monitoring via teledermatological visits
Treatment: Collection of patient data
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- A Non-Interventional Study to Compare Digital Monitoring of Patients With Chronic Spontaneous Urticaria by Telemedicine to Face-to-Face Visits in Germany (DigiMoc)
- Record updated
- 16 July 2025